Delivery Order SPE2DB20D1100-SPE2DB25FE4T0
- Not listed
- The Defense Logistics Agency awarded a $1,117.68 delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% eye emulsion (60 count) on July 22, 2025, with an ultimate completion date of July 23, 2025. This firm fixed price delivery order represents a non-competitive set-aside contract and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Restasis 0.05% Eye Emulsion in 60-count units, with a contract ceiling value of $22,836.31. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award selection. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of August 21, 2025. This delivery order...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,318.51 on July 28, 2025, for the supply of Restasis 0.05% eye emulsion (30 single-use vials). This firm fixed price delivery order, with an ultimate completion date of July 29, 2025, represents a small-value transaction issued under a larger indefinite delivery contract vehicle. The award was made through competitive procurement with no set-aside designation, and the product will be delivered to...
- The Defense Logistics Agency awarded a $6,297.40 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Restasis 0.05% eye emulsion (60-unit package). This non-set-aside, competitively awarded contract features firm fixed pricing and is scheduled for completion by July 29, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's larger...
- The Defense Logistics Agency awarded a $1,293.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (60-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside contract was competitively awarded and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $12,777.96 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Restasis 0.05% Eye Emulsion in 60-count units. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive procurement. Performance will be completed by July 29, 2025, with work performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Restasis 0.05% eye emulsion (30 count) at a firm fixed price of $1,117.80. The contract, which is non-set-aside and competitively awarded, has an ultimate completion date of August 4, 2025, with performance to be completed at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Restasis 0.05% Eye Emulsion in quantities of 30 units, with a firm fixed price ceiling value of $2,716.92. This is a non-set-aside award with an ultimate completion date of August 11, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a continuation of the company's extensive...
- The Defense Logistics Agency awarded a delivery order valued at $2,444.74 to AmerisourceBergen Drug Corp for the supply of Restasis 0.05% Eye Emulsion (60 units) on August 7, 2025, with completion targeted for August 8, 2025. This is a firm fixed-price, non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Restasis 0.05% Eye Emulsion in 60-unit quantities, with a ceiling value of $5,957.02 and an ultimate completion date of August 28, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a child contract under a larger vehicle. The place of performance is the company's corporate office location in Conshohocken,...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE4T0Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $14,980.58 to AmerisourceBergen Drug Corp for the supply of Restasis 0.05% Eye Emulsion (60-count units) on September 4, 2025, with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of the vendor's extensive pharmaceutical supply relationship with the federal government. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and running through December 2026. This prime contract framework enables AmerisourceBergen to supply a broad range of pharmaceutical products, medical devices, and healthcare commodities to support military healthcare programs and the Defense Health Agency worldwide. The company's significant presence as a federal pharmaceutical vendor is reinforced by its portfolio of competitively awarded contracts spanning multiple therapeutic domains and order values, demonstrating its capability to meet diverse federal medical procurement requirements at scale.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.0k | 9/4/25 |